AZN vs. MRNA

Last updated Apr 2, 2026

Compare and contrast key facts about AstraZeneca PLC (AZN) and Moderna, Inc. (MRNA).

Performance

AZN vs. MRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in AstraZeneca PLC (AZN) and Moderna, Inc. (MRNA). The values are adjusted to include any dividend payments, if applicable.

AZN vs. MRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
AZN AstraZeneca PLC	11.46%	43.30%	-0.62%	1.44%	19.14%	19.66%	3.12%	35.68%	-0.52%
MRNA Moderna, Inc.	69.65%	-29.08%	-58.19%	-44.63%	-29.28%	143.11%	434.10%	28.09%	-17.90%

Fundamentals

Market Cap AZN : $313.54B MRNA : $19.61B
EPS AZN : $6.55 MRNA : -$7.24
PS Ratio AZN : 5.33 MRNA : 10.04
PB Ratio AZN : 6.44 MRNA : 2.27
Total Revenue (TTM) AZN : $58.74B MRNA : $1.94B
Gross Profit (TTM) AZN : $48.11B MRNA : $274.00M
EBITDA (TTM) AZN : $19.83B MRNA : -$2.61B

Returns By Period

In the year-to-date period, AZN achieves a 11.46% return, which is significantly lower than MRNA's 69.65% return.

AZN

• 1D: 1.78%
• 1M: -1.47%
• YTD: 11.46%
• 6M: 21.46%
• 1Y: 42.12%
• 3Y*: 15.74%
• 5Y*: 17.86%
• 10Y*: 16.92%

MRNA

• 1D: -1.52%
• 1M: -5.33%
• YTD: 69.65%
• 6M: 81.27%
• 1Y: 84.20%
• 3Y*: -31.19%
• 5Y*: -17.71%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

AZN vs. MRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AZN

AZN Risk / Return Rank: 84
AZN Sharpe Ratio Rank: 85
AZN Sortino Ratio Rank: 82
AZN Omega Ratio Rank: 80
AZN Calmar Ratio Rank: 87
AZN Martin Ratio Rank: 85

MRNA

MRNA Risk / Return Rank: 77
MRNA Sharpe Ratio Rank: 80
MRNA Sortino Ratio Rank: 78
MRNA Omega Ratio Rank: 73
MRNA Calmar Ratio Rank: 78
MRNA Martin Ratio Rank: 74

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AZN vs. MRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for AstraZeneca PLC (AZN) and Moderna, Inc. (MRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	AZN	MRNA	Difference
Sharpe ratio Return per unit of total volatility	1.56	1.28	+0.28
Sortino ratio Return per unit of downside risk	2.25	2.02	+0.23
Omega ratio Gain probability vs. loss probability	1.29	1.24	+0.05
Calmar ratio Return relative to maximum drawdown	3.25	2.15	+1.10
Martin ratio Return relative to average drawdown	8.16	4.44	+3.72
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

AZN vs. MRNA - Sharpe Ratio Comparison

The current AZN Sharpe Ratio is 1.56, which is comparable to the MRNA Sharpe Ratio of 1.28. The chart below compares the historical Sharpe Ratios of AZN and MRNA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	AZN	MRNA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.56	1.28	+0.28
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.75	-0.27	+1.02
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.68	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.51	0.20	+0.31

Correlation

The correlation between AZN and MRNA is 0.20, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

AZN vs. MRNA - Dividend Comparison

AZN's dividend yield for the trailing twelve months is around 2.65%, while MRNA has not paid dividends to shareholders.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
AZN AstraZeneca PLC	2.65%	1.70%	2.27%	2.15%	2.12%	2.35%	2.80%	2.81%	3.69%	3.95%	5.01%	4.06%
MRNA Moderna, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Drawdowns

AZN vs. MRNA - Drawdown Comparison

The maximum AZN drawdown since its inception was -48.94%, smaller than the maximum MRNA drawdown of -95.38%. Use the drawdown chart below to compare losses from any high point for AZN and MRNA.

Drawdown Indicators

	AZN	MRNA	Difference
Max Drawdown Largest peak-to-trough decline	-48.94%	-95.38%	+46.44%
Max Drawdown (1Y) Largest decline over 1 year	-12.24%	-35.51%	+23.27%
Max Drawdown (5Y) Largest decline over 5 years	-27.87%	-95.38%	+67.51%
Max Drawdown (10Y) Largest decline over 10 years	-27.87%	—	—
Current Drawdown Current decline from peak	-3.70%	-89.67%	+85.97%
Average Drawdown Average peak-to-trough decline	-11.38%	-55.87%	+44.49%
Ulcer Index Depth and duration of drawdowns from previous peaks	4.88%	17.21%	-12.33%

Volatility

AZN vs. MRNA - Volatility Comparison

The current volatility for AstraZeneca PLC (AZN) is 7.15%, while Moderna, Inc. (MRNA) has a volatility of 22.27%. This indicates that AZN experiences smaller price fluctuations and is considered to be less risky than MRNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	AZN	MRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	7.15%	22.27%	-15.12%
Volatility (6M) Calculated over the trailing 6-month period	19.20%	50.95%	-31.75%
Volatility (1Y) Calculated over the trailing 1-year period	27.33%	66.40%	-39.07%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	23.85%	66.59%	-42.74%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	24.90%	72.29%	-47.39%

Financials